Frazier Life Sciences Management
Latest statistics and disclosures from Frazier Life Sciences Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NAMS, MIRM, KRYS, HLVX, PHAT, and represent 41.92% of Frazier Life Sciences Management's stock portfolio.
- Added to shares of these 10 stocks: IRON (+$44M), ERAS (+$38M), ANAB (+$32M), RARE (+$18M), SVRA (+$17M), MREO (+$16M), AGIO (+$15M), IMTX (+$13M), HLVX (+$12M), ELEV (+$8.0M).
- Started 8 new stock positions in IMTX, ADVM, ERAS, IMCR, RARE, ELEV, DSGN, MREO.
- Reduced shares in these 10 stocks: Alpine Immune Sciences (-$124M), APLS (-$52M), AVTE (-$36M), GPCR (-$27M), Deciphera Pharmaceuticals (-$23M), MRUS (-$22M), Adverum Biotechnologies (-$15M), PCVX (-$7.6M), NTLA (-$5.6M), TARS (-$5.4M).
- Sold out of its positions in Adverum Biotechnologies, AVTE, Alpine Immune Sciences, APLS, BLUE, Deciphera Pharmaceuticals, GRTS, NTLA, GPCR.
- Frazier Life Sciences Management was a net seller of stock by $-64M.
- Frazier Life Sciences Management has $2.1B in assets under management (AUM), dropping by -9.80%.
- Central Index Key (CIK): 0001892134
Tip: Access up to 7 years of quarterly data
Positions held by Frazier Life Sciences Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 49 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 11.0 | $235M | 12M | 19.21 |
|
|
| Mirum Pharmaceuticals (MIRM) | 10.4 | $222M | 6.5M | 34.19 |
|
|
| Krystal Biotech (KRYS) | 8.5 | $182M | 989k | 183.64 |
|
|
| Hillevax (HLVX) | 7.2 | $154M | +8% | 11M | 14.46 |
|
| Phathom Pharmaceuticals (PHAT) | 4.9 | $104M | 10M | 10.30 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 4.6 | $97M | +8% | 2.4M | 41.06 |
|
| Bridgebio Pharma (BBIO) | 4.3 | $92M | +6% | 3.6M | 25.33 |
|
| Arcutis Biotherapeutics (ARQT) | 3.8 | $82M | 8.8M | 9.30 |
|
|
| Disc Medicine (IRON) | 3.7 | $79M | +123% | 1.8M | 45.07 |
|
| Vaxcyte (PCVX) | 3.7 | $79M | -8% | 1.0M | 75.51 |
|
| Edgewise Therapeutics (EWTX) | 3.1 | $67M | +12% | 3.7M | 18.01 |
|
| Anaptysbio Inc Common (ANAB) | 2.5 | $54M | +140% | 2.2M | 25.06 |
|
| Verona Pharma Sponsored Ads (VRNA) | 2.2 | $48M | +9% | 3.3M | 14.46 |
|
| Kalvista Pharmaceuticals (KALV) | 2.0 | $43M | 3.7M | 11.78 |
|
|
| Tarsus Pharmaceuticals (TARS) | 2.0 | $43M | -11% | 1.6M | 27.18 |
|
| Revolution Medicines (RVMD) | 1.8 | $39M | 998k | 38.81 |
|
|
| Erasca (ERAS) | 1.8 | $38M | NEW | 16M | 2.36 |
|
| Agios Pharmaceuticals (AGIO) | 1.8 | $38M | +66% | 872k | 43.12 |
|
| Soleno Therapeutics (SLNO) | 1.7 | $36M | 876k | 40.80 |
|
|
| Rocket Pharmaceuticals (RCKT) | 1.6 | $34M | 1.6M | 21.53 |
|
|
| Savara (SVRA) | 1.5 | $33M | +103% | 8.2M | 4.03 |
|
| Oric Pharmaceuticals (ORIC) | 1.4 | $29M | 4.1M | 7.07 |
|
|
| Cg Oncology (CGON) | 1.1 | $24M | 770k | 31.57 |
|
|
| Pepgen (PEPG) | 1.1 | $24M | 1.5M | 15.96 |
|
|
| Merus N V (MRUS) | 1.0 | $22M | -50% | 373k | 59.17 |
|
| Trevi Therapeutics (TRVI) | 1.0 | $22M | 7.4M | 2.98 |
|
|
| Silence Therapeutics Ads (SLN) | 1.0 | $22M | 1.1M | 19.00 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 0.8 | $18M | NEW | 425k | 41.10 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.8 | $16M | 4.6M | 3.48 |
|
|
| Cerevel Therapeutics Hldng I (CERE) | 0.8 | $16M | 393k | 40.89 |
|
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.7 | $16M | NEW | 4.4M | 3.60 |
|
| Immatics SHS (IMTX) | 0.6 | $13M | NEW | 1.2M | 11.62 |
|
| Tyra Biosciences (TYRA) | 0.6 | $13M | 832k | 15.99 |
|
|
| Macrogenics (MGNX) | 0.6 | $13M | +21% | 3.0M | 4.25 |
|
| Applied Therapeutics (APLT) | 0.5 | $11M | +17% | 2.3M | 4.67 |
|
| Puma Biotechnology (PBYI) | 0.5 | $10M | +8% | 3.1M | 3.26 |
|
| 89bio (ETNB) | 0.4 | $8.0M | 1.0M | 8.01 |
|
|
| Elevation Oncology (ELEV) | 0.4 | $8.0M | NEW | 3.0M | 2.70 |
|
| Cogent Biosciences (COGT) | 0.4 | $7.9M | 937k | 8.43 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 0.4 | $7.6M | 470k | 16.25 |
|
|
| Arvinas Ord (ARVN) | 0.4 | $7.6M | 285k | 26.62 |
|
|
| Adverum Biotechnologies Com New (ADVM) | 0.3 | $7.3M | NEW | 1.1M | 6.86 |
|
| Allogene Therapeutics (ALLO) | 0.3 | $6.7M | 2.9M | 2.33 |
|
|
| An2 Therapeutics (ANTX) | 0.2 | $4.5M | +50% | 2.1M | 2.15 |
|
| Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.2 | $4.4M | 500k | 8.72 |
|
|
| Design Therapeutics (DSGN) | 0.2 | $4.0M | NEW | 1.2M | 3.35 |
|
| Immunocore Hldgs Ads (IMCR) | 0.2 | $3.7M | NEW | 109k | 33.89 |
|
| Metagenomi (MGX) | 0.0 | $1.0M | -11% | 246k | 4.08 |
|
| Aclaris Therapeutics (ACRS) | 0.0 | $291k | 264k | 1.10 |
|
Past Filings by Frazier Life Sciences Management
SEC 13F filings are viewable for Frazier Life Sciences Management going back to 2022
- Frazier Life Sciences Management 2024 Q2 filed Aug. 15, 2024
- Frazier Life Sciences Management 2024 Q1 filed May 15, 2024
- Frazier Life Sciences Management 2023 Q4 filed Feb. 14, 2024
- Frazier Life Sciences Management 2023 Q3 filed Nov. 14, 2023
- Frazier Life Sciences Management 2023 Q2 filed Aug. 14, 2023
- Frazier Life Sciences Management 2023 Q1 filed May 15, 2023
- Frazier Life Sciences Management 2022 Q4 restated filed Feb. 7, 2023
- Frazier Life Sciences Management 2022 Q4 filed Feb. 3, 2023
- Frazier Life Sciences Management 2022 Q3 filed Nov. 14, 2022
- Frazier Life Sciences Management 2022 Q2 filed Aug. 10, 2022
- Frazier Life Sciences Management 2022 Q1 filed May 16, 2022